Literature DB >> 406834

Bactericidal activity of macromomycin, a antitumor antibiotic.

F L Buckmire, J L Winkelhake.   

Abstract

Susceptibility testing by the broth dilution method showed that all the gram-positive but only some of the gram-negative bacteria tested were susceptible to the antitumor antibiotic, macromomycin (MCR; NSC 170105). The minimal inhibitory concentration for the susceptible organisms was less than 3 mug/ml. The action of MCR was bactericidal; however, at very high concentrations (50 mug/ml and above) some organisms occasionally escaped death. None of the escaped organisms was resistant to MCR. In combination with other commonly used antibiotics, MCR displayed partial synergy for Pseudomonas aeruginosa (from a minimal inhibitory concentration of >100 to 12.5 mug/ml with 100 mug of chloramphenicol per ml) and for Bacillus pumilus and Staphylococcus aureus (from 1.6 to 0.4 mug/ml and below) with polymyxin B. As with mammalian cells, (125)I-labeled MCR was irreversibly bound to both gram-positive and -negative bacteria. Treatment with trypsin of the (125)I-labeled MCR-exposed cells did not release the bound MCR or reverse its lethal effect. When in solution in a protective buffer at 4 degrees C, MCR was stable for up to 45 days; at 37 degrees C, however, 25% of its bactericidal activity was lost in 72 h. Loss of activity was enhanced 16-fold in the presence of both heated and unheated pooled human sera. Urine had no effect on the activity of MCR.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 406834      PMCID: PMC352120          DOI: 10.1128/AAC.11.6.1010

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Colicinogeny and related phenomena.

Authors:  K G Hardy
Journal:  Bacteriol Rev       Date:  1975-12

2.  Further purification and characterization of macromomycin.

Authors:  T Yamashita; N Naoi; K Watanabe
Journal:  J Antibiot (Tokyo)       Date:  1976-04       Impact factor: 2.649

3.  In vitro studies on macromomycin (NSC-170105): effects on cultured TA3Ha and L1210 cells.

Authors:  M M Lippman
Journal:  Cancer Chemother Rep       Date:  1974 Mar-Apr

4.  Macromomycin, an inhibitor of the membrane function of tumor cells.

Authors:  T Kunimoto; M Hori; H Umezawa
Journal:  Cancer Res       Date:  1972-06       Impact factor: 12.701

5.  Defined medium for growth of Haemophilus influenzae.

Authors:  R M Herriott; E Y Meyer; M Vogt; M Modan
Journal:  J Bacteriol       Date:  1970-02       Impact factor: 3.490

6.  Aglycosylantibody. Effects of exoglycosidase treatments on autochthonous antibody survival time in the circulation.

Authors:  J L Winkelhake; G L Nicolson
Journal:  J Biol Chem       Date:  1976-02-25       Impact factor: 5.157

7.  Affinity chromatography of anti-meningococcal antiserum.

Authors:  J L Winkelhake; D L Kasper
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

8.  Identification and quantitation of capsular antigen in capsulated and noncapsulated strains of Haemophilus influenzae type b by crossed-immunoelectrophoresis.

Authors:  F L Buckmire
Journal:  Infect Immun       Date:  1976-06       Impact factor: 3.441

9.  Effects of procedural variations on the activity of aminoglycosides in vitro.

Authors:  C C Sanders; W E Sanders
Journal:  Am J Clin Pathol       Date:  1975-03       Impact factor: 2.493

10.  Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma.

Authors:  M M Lippman; W R Laster; B J Abbott; J Venditti; M Baratta
Journal:  Cancer Res       Date:  1975-04       Impact factor: 12.701

View more
  1 in total

1.  Routine use of BACTEC 16B bottles to remove antibacterial and antitumor agents from blood cultures of cancer patients.

Authors:  R L Hopfer; D G Moore; V Fainstein; S Watkins; M Wenglar
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.